Teladoc Q1 revenue $629M (+11% YoY); net loss $0.42/sh; guides Q2 rev $635-660M

Teladoc Health, Inc.

2023-Q1 EPS reported -$0.42 revenue$629,244,000

Revenue $629.2M (+11% YoY); Integrated Care $350M (+5%), BetterHelp $279M (+21%).
Net loss $69.2M ($0.42/sh) vs $6.67B loss in Q1 2022 which included $6.6B goodwill impairment.
Adjusted EBITDA $52.8M (-3% YoY); Integrated Care segment adj. EBITDA +51% to $35.1M, BetterHelp -41% to $17.6M.
Q2 2023 guidance: rev $635-660M, adj. EBITDA $60-68M, net loss per share ($0.55)-($0.45).
Full year 2023 guidance: rev $2.575-2.675B, adj. EBITDA $285-325M, net loss per share ($1.70)-($1.25).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Teladoc Health, Inc. reported first quarter ended March 31, 2023 results: revenue $629.2 million, net income Net loss of $69.2 million, EPS $0.42 per share. Guidance initiated.

Period: first quarter ended March 31, 2023
Revenue: $629.2 million
Net income: Net loss of $69.2 million
EPS: $0.42 per share
Guidance: initiated
Result: reported results

Exact text from the filing

● First quarter 2023 revenue grows 11% year-over-year to $629.2 million ● First quarter 2023 net loss of $69.2 million, or $0.42 per share ● First quarter adjusted EBITDA totaled $52.8 million

View on SEC.gov

Browse all earnings releases →

Teladoc Health, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-006823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.